Phillips-Medisize announces expansion of global manufacturing capacity

Phillips-Medisize, a Molex company, has announced the expansion of its global manufacturing footprint, along with extended product design, development, and manufacturing capabilities to streamline the delivery of products and solutions. 

The company’s global reach now encompasses 36 facilities with scalable, end-to-end capabilities tailored to help customers bring products to market quickly and efficiently.

Paul Chaffin, president, medical and pharmaceutical solutions, Molex, said: “As the preferred partner for leading global customers, we continually invest in new talent and technologies that increase the capacity and capabilities of Phillips-Medisize across the entire value chain. Our expanded global reach and resources will enable us to solve complex development and manufacturing challenges while meeting escalating customer demands for more localised production, supply chain management and accelerated go-to-market strategies.”

To address growing production demands from customers in continental Europe, Phillips-Medisize is building a medical manufacturing facility in Katowice, Poland. Slated to open in 2022, the site will complement production sites and innovation centres in Asia, Europe, India, Mexico and North America. Phillips-Medisize also is expanding production capacity in Suzhou, China to serve both global and regional pharmaceutical and medtech customers. Also, the upgrade of an existing Molex production facility in Little Rock, Arkansas, is underway, enabling Phillips-Medisize to keep pace with ever-increasing requirements in the U.S. for diagnostic device manufacturing. 

Once these expansions are complete Phillips-Medisize will offer nearly three million square feet/280,000 square meters of country- and region-specific manufacturing space and R&D capabilities worldwide. The company also will support 600,000 square feet/55,000 square meters of Class 7 and 8 cleanrooms, which complement existing tool building sites.

As part of its medical-device manufacturing solutions, Phillips-Medisize focusses on design for manufacturability and assembly excellence. Proven front-end innovation, human-factors engineering, and quality are integrated with regulatory adherence to reduce go-to-market risk and cost. Expanded capabilities in complex moulding, drug, and reagent handling, as well as final packaging and serialisation, enable customers to consolidate global supply chains while optimising go-to-market strategies.

Phillips-Medisize’s combined expertise in plastics, metals, electronics, and connectivity ease the development of different solutions, including combination devices such as needle-based injection systems and wearable injection technologies.